{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:50Z","timestamp":1788401630285,"version":"build-2803163510"},"reference-count":49,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Public Health Surveill"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the advent of new vaccines, including the COVID-19 vaccines introduced during the recent pandemic, the need for near real-time active surveillance has increased to support timely regulatory decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the feasibility of sequential monitoring for potential adverse events following immunization in Korea, focusing on COVID-19 vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based study used a linked database that combined the COVID-19 registry with national health insurance claims data. Participants included individuals older than 12 years who received either monovalent or bivalent COVID-19 vaccines in Korea between February 2021 and March 2023. Monthly retrospective sequential testing was performed for 3 prespecified outcomes (acute myocardial infarction, myocarditis, and anaphylaxis) as well as a negative control event (colonic diverticulitis). A Poisson-based maximized sequential probability ratio test was applied to compare postvaccination incidence rates with historical background rates, accounting for multiple testing and claims processing delays. Analyses were stratified by age group, vaccine platform, and dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included over 43 million monovalent and 6.3 million bivalent vaccine recipients. Sequential analyses identified statistical signals for myocarditis following mRNA vaccines in individuals aged 12 to 64 years and protein subunit vaccines in those aged 40 to 64 years. Signals for anaphylaxis were observed following mRNA and nonreplicating viral vector vaccines in individuals older than 18 years. No safety signals were identified for acute myocardial infarction or colonic diverticulitis. Sequential monitoring detected signals for myocarditis and anaphylaxis before regulatory authorities took safety actions, with the earliest signals observed on September 30, 2021, and April 30, 2021, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Near real-time sequential testing detected statistical safety signals for myocarditis and anaphylaxis following COVID-19 vaccination. These signals were recognized by the regulatory authority as being associated with the vaccines, demonstrating the potential of this approach to detect signals requiring further causality assessments, particularly for newly introduced vaccines at an early stage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/75094","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:05:09Z","timestamp":1764831909000},"page":"e75094-e75094","source":"Crossref","is-referenced-by-count":1,"title":["Active Surveillance for COVID-19 Vaccine Safety Using Sequential Analysis in Korea: Population-Based Retrospective Observational Study"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-1286","authenticated-orcid":false,"given":"Na-Young","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7221-4265","authenticated-orcid":false,"given":"Haerin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9601-3786","authenticated-orcid":false,"given":"Heehyun","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4292-049X","authenticated-orcid":false,"given":"Suvin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-3772","authenticated-orcid":false,"given":"Joongyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-6522","authenticated-orcid":false,"given":"Hyesook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1153-9928","authenticated-orcid":false,"given":"Nam-Kyong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project","volume":"127","author":"Yih","journal-title":"Pediatrics"},{"key":"R2","unstructured":"COVID-19 vaccines: safety surveillance manual. World Health Organization; 2020. URL: https:\/\/www.who.int\/docs\/default-source\/covid-19-vaccines-safety-surveillance-manual\/covid19vaccines_manual_aefi_20210104.pdf [Accessed 21-03-2026]"},{"issue":"10","key":"R3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40264-024-01449-x","article-title":"What is the safety of COVID-19 vaccines in immunocompromised patients? Results from the European \u201cCOVID Vaccine Monitor\u201d active surveillance study","volume":"47","author":"Bellitto","journal-title":"Drug Saf"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.02.065","article-title":"Overview of U.S. COVID-19 vaccine safety surveillance systems","volume":"42","author":"Gee","journal-title":"Vaccine (Auckl)"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.08.012","article-title":"ADVANCE: towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases","volume":"38 Suppl 2","author":"Bollaerts","journal-title":"Vaccine (Auckl)"},{"issue":"42","key":"R6","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: Successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","journal-title":"Vaccine (Auckl)"},{"key":"R7","unstructured":"Vaccines & allergenics. Biologics Effectiveness and Safety (BEST) Initiative. 2023. URL: https:\/\/bestinitiative.org\/vaccines-and-allergenics [Accessed 15-02-2025]"},{"issue":"10 Supl 2","key":"R8","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events","volume":"45","author":"Lieu","journal-title":"Med Care"},{"issue":"2","key":"R9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project","volume":"171","author":"Greene","journal-title":"Am J Epidemiol"},{"issue":"11","key":"R10","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011","volume":"30","author":"Tse","journal-title":"Vaccine (Auckl)"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/infdis\/jiaa543","article-title":"Guillain-Barr\u00e9 syndrome after high-dose influenza vaccine administration in the United States, 2018-2019 season","volume":"223","author":"Perez-Vilar","journal-title":"J Infect Dis"},{"issue":"2","key":"R12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink project","volume":"41","author":"Lee","journal-title":"Am J Prev Med"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/INF.0b013e3181af8605","article-title":"Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine","volume":"29","author":"Belongia","journal-title":"Pediatr Infect Dis J"},{"issue":"46","key":"R14","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","journal-title":"Vaccine (Auckl)"},{"issue":"6","key":"R15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1808","article-title":"Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine","volume":"144","author":"Donahue","journal-title":"Pediatrics"},{"issue":"22","key":"R16","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Tseng","journal-title":"Vaccine (Auckl)"},{"issue":"14","key":"R17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","journal-title":"JAMA"},{"issue":"2","key":"R18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-057313","article-title":"Safety of COVID-19 vaccination in United States children ages 5 to 11 years","volume":"150","author":"Hause","journal-title":"Pediatrics"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-061894","article-title":"Safety of COVID-19 mRNA vaccination among young children in the vaccine safety datalink","volume":"152","author":"Goddard","journal-title":"Pediatrics"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.088","article-title":"Post-licensure rapid immunization safety monitoring program (PRISM) data characterization","volume":"31","author":"Baker","journal-title":"Vaccine (Auckl)"},{"issue":"5","key":"R21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/pds.3908","article-title":"Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System","volume":"25","author":"Yih","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"45","key":"R22","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.1016\/j.vaccine.2022.09.060","article-title":"Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years","volume":"40","author":"Lloyd","journal-title":"Vaccine (Auckl)"},{"issue":"4","key":"R23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8192","article-title":"Safety of ancestral monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 vaccines in US children aged 6 months to 17 years","volume":"7","author":"Hu","journal-title":"JAMA Netw Open"},{"issue":"7","key":"R24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamapediatrics.2023.1440","article-title":"Safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years","volume":"177","author":"Hu","journal-title":"JAMA Pediatr"},{"key":"R25","unstructured":"VAC4EU studies. Vaccine Monitoring Collaboration for Europe. 2023. URL: https:\/\/vac4eu.org\/studies\/ [Accessed 15-02-2025]"},{"issue":"4","key":"R26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/pds.4173","article-title":"Assessing recording delays in general practice records to inform near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD)","volume":"26","author":"Leite","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"49 Pt B","key":"R27","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1016\/j.vaccine.2017.09.022","article-title":"Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD)","volume":"35","author":"Leite","journal-title":"Vaccine (Auckl)"},{"issue":"4","key":"R28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/pharmaceutics4040607","article-title":"Signal detection and monitoring based on longitudinal healthcare data","volume":"4","author":"Suling","journal-title":"Pharmaceutics"},{"issue":"12","key":"R29","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/pds.2237","article-title":"Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database","volume":"20","author":"Choi","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"R30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/pds.1902","article-title":"Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database","volume":"19","author":"Choi","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"R31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","article-title":"Data resource profile: the national health information database of the National Health Insurance Service in South Korea","volume":"46","author":"Cheol Seong","journal-title":"Int J Epidemiol"},{"issue":"1","key":"R32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.24171\/j.phrp.2023.0026","article-title":"A framework for nationwide COVID-19 Vaccine safety research in the Republic of Korea: the COVID-19 Vaccine Safety Research Committee","volume":"14","author":"Jeong","journal-title":"Osong Public Health Res Perspect"},{"key":"R33","unstructured":"Law B Pim C . Third update\u2014priority list of adverse events of special interest: COVID-19. Zenodo. 2022. URL: https:\/\/zenodo.org\/records\/6669790 [Accessed 21-03-2026]"},{"key":"R34","unstructured":"COVID\u201119 vaccine safety surveillance: active monitoring master protocol. Center for Biologics Evaluation and Research (CBER), Office of Biostatistics and Epidemiology; 2021. URL: https:\/\/bestinitiative.org\/wp-content\/uploads\/2021\/02\/C19-Vaccine-Safety-Protocol-2021.pdf [Accessed 21-03-2026]"},{"issue":"2","key":"R35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"R36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/all.15975","article-title":"Risk of anaphylaxis after COVID-19 vaccination in South Korea: a nationwide self-controlled case series analysis","volume":"79","author":"Yoon","journal-title":"Allergy"},{"issue":"3","key":"R37","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11030613","article-title":"Anaphylactic reactions to COVID-19 vaccines: an updated assessment based on pharmacovigilance data","volume":"11","author":"Boufidou","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"R38","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis","volume":"20","author":"Sobczak","journal-title":"Clin Mol Allergy"},{"issue":"2","key":"R39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.24171\/j.phrp.2023.0343","article-title":"The COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea","volume":"15","author":"Jeong","journal-title":"Osong Public Health Res Perspect"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.893484","article-title":"Vaccine safety surveillance using routinely collected healthcare data-an empirical evaluation of epidemiological designs","volume":"13","author":"Schuemie","journal-title":"Front Pharmacol"},{"issue":"2","key":"R41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020","volume":"41","author":"Moll","journal-title":"Vaccine (Auckl)"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Kulldorff M . Sequential statistical methods for prospective postmarketing safety surveillance. In: Strom BL Kimmel SE Hennessy S , editors. Pharmacoepidemiology. 5th ed. Wiley; 2012:852-867. [doi: 10.1002\/9781119959946]","DOI":"10.1002\/9781119959946.ch46"},{"issue":"3","key":"R43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/biom.12324","article-title":"Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance","volume":"71","author":"Silva","journal-title":"Biometrics"},{"issue":"1","key":"R44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/07474946.2011.539924","article-title":"A maximized sequential probability ratio test for drug and vaccine safety surveillance","volume":"30","author":"Kulldorff","journal-title":"Seq Anal"},{"issue":"5","key":"R45","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.therap.2023.03.003","article-title":"Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: the French perspective","volume":"78","author":"Salvo","journal-title":"Therapie"},{"key":"R46","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3\u20116 May 2021. European Medicines Agency. URL: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021 [Accessed 15-02-2025]"},{"issue":"2","key":"R47","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.vaccine.2022.11.069","article-title":"Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older","volume":"41","author":"Wong","journal-title":"Vaccine (Auckl)"},{"issue":"4","key":"R48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the vaccine safety datalink","volume":"5","author":"Hanson","journal-title":"JAMA Netw Open"},{"issue":"35","key":"R49","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1016\/j.vaccine.2022.07.007","article-title":"Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination","volume":"40","author":"Goddard","journal-title":"Vaccine (Auckl)"}],"container-title":["JMIR Public Health and Surveillance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publichealth.jmir.org\/2026\/1\/e75094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:05:59Z","timestamp":1782842759000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealth.jmir.org\/2026\/1\/e75094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":49,"URL":"https:\/\/doi.org\/10.2196\/75094","relation":{},"ISSN":["2369-2960"],"issn-type":[{"value":"2369-2960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"v12i10e75094"}}